Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers
Hong Cui,Cai-Yun Zhao,Yuan Lv,Min-Ji Wei,Yan Zhu,Yun Li,Ya-Hong Xia,Yan Liu,Ji-Hong Tian,Pu Zhang
DOI: https://doi.org/10.1007/s13318-020-00605-9
2020-01-01
European Journal of Drug Metabolism and Pharmacokinetics
Abstract:Background and Objective Exenatide promotes insulin secretion and inhibits postprandial glucagon secretion. Polyethylene glycolated exenatide injection (PB-119), a derivative obtained by modification of exenatide, is more stable in metabolic behavior than exenatide in vivo. Our study aimed to evaluate the safety, tolerability and pharmacokinetic characteristics of polyethylene glycolated exenatide as a single subcutaneous injection in healthy volunteers. Methods Seventy subjects were randomly assigned to 8 incremental dosage groups (2, 5, 10, 25, 50, 100, 200 and 400 mu g). The 2- to 50-mu g groups had 8 subjects in each group (the ratio of test preparation to placebo was 3:1), and the 100- to 400-mu g groups had 10 subjects in each group (the ratio of test preparation to placebo was 4:1). All the subjects received a single subcutaneous injection of polyethylene glycolated exenatide and placebo according to the dosage groups. The tolerability test was conducted in the 2- to 10-mu g groups. The pharmacokinetic test was carried out in the 25- to 400-mu g groups, and plasma samples were collected to determine the pharmacokinetics of polyethylene glycolated exenatide. After medication, the vital signs of the subjects were monitored, and laboratory tests and electrocardiogram tests were carried out regularly in all the subjects. Results All 70 subjects completed the experiment. Except for the 5-mu g and 10-mu g groups, the safety and tolerability tests showed no adverse reactions in the 2-mu g to 50-mu g groups. Several subjects in the 100-mu g and 200-mu g groups had tolerable gastrointestinal tract reactions, and all subjects in the 400-mu g group experienced adverse reactions, mainly gastrointestinal tract reactions and liver dysfunction. The pharmacokinetics of polyethylene glycolated exenatide was studied in 36 subjects, which showed slow absorption, a mean peak time of 20-40 h, and a mean elimination half-life of 51-64 h. Conclusion The administration of polyethylene glycolated exenatide injection at a single dose of 2-200 mu g is safe and tolerable for healthy volunteers. Once-weekly polyethylene glycolated exenatide injection can be recommended.